228 related articles for article (PubMed ID: 33536913)
21. Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
Zhao JX; Liu H; Lv J; Yang XJ
Eur Rev Med Pharmacol Sci; 2014; 18(17):2428-34. PubMed ID: 25268086
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
[TBL] [Abstract][Full Text] [Related]
23. Nanocurcumin and curcumin prevent N, N'-methylenebisacrylamide-induced liver damage and promotion of hepatic cancer cell growth.
Atia MM; Abdel-Tawab HS; Mostafa AM; Mobarak SA
Sci Rep; 2022 May; 12(1):8319. PubMed ID: 35585174
[TBL] [Abstract][Full Text] [Related]
24. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
25. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.
Weir NM; Selvendiran K; Kutala VK; Tong L; Vishwanath S; Rajaram M; Tridandapani S; Anant S; Kuppusamy P
Cancer Biol Ther; 2007 Feb; 6(2):178-84. PubMed ID: 17218783
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
27. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
28. G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway.
Qiao HF; Liu YL; You J; Zheng YL; Chen LP; Lu XY; Du L; Shan F; Liu MH
J Reprod Immunol; 2020 Aug; 140():103129. PubMed ID: 32334286
[TBL] [Abstract][Full Text] [Related]
29. Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells.
Duan J; Zhang Z; Du J; Zhang J; Li M; Li C
Onco Targets Ther; 2023; 16():425-440. PubMed ID: 37359351
[TBL] [Abstract][Full Text] [Related]
30. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
[TBL] [Abstract][Full Text] [Related]
31. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.
Zhang R; Yang X; Roque DM; Li C; Lin J
PLoS One; 2021; 16(4):e0240145. PubMed ID: 33909625
[TBL] [Abstract][Full Text] [Related]
32. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
34. miR-34c Targets MET to Improve the Anti-Tumor Effect of Cisplatin on Ovarian Cancer.
Yang S; Li Z; Luo R
Onco Targets Ther; 2020; 13():2887-2897. PubMed ID: 32308421
[TBL] [Abstract][Full Text] [Related]
35. Pentagalloyl Glucose and Cisplatin Combination Treatment Exhibits a Synergistic Anticancer Effect in 2D and 3D Models of Head and Neck Carcinoma.
Kantapan J; Intachai N; Khamto N; Meepowpan P; Sangthong P; Wantanajittikul K; Dechsupa N; Chitapanarux I
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890129
[TBL] [Abstract][Full Text] [Related]
36. Nanocurcumin Inhibits Angiogenesis via Down-regulating hif1a/VEGF-A Signaling in Zebrafish.
Cao Z; He S; Peng Y; Liao X; Lu H
Curr Neurovasc Res; 2020; 17(2):147-154. PubMed ID: 32031071
[TBL] [Abstract][Full Text] [Related]
37. Suppression of PI3K/Akt/mTOR Signaling Pathway and Antioxidant System and Reversal of Cancer Cells Resistance to Cisplatin under the Effect of Curcumin.
Kalinina EV; Hasan AAS; Tatarskiy VV; Volodina YL; Petrova АS; Novichkova MD; Zhdanov DD; Nurmuradov NK; Chernov NN; Shtil AA
Bull Exp Biol Med; 2022 Jul; 173(3):371-375. PubMed ID: 35854021
[TBL] [Abstract][Full Text] [Related]
38. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
39. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin.
Seo JH; Jeong KJ; Oh WJ; Sul HJ; Sohn JS; Kim YK; Cho DY; Kang JK; Park CG; Lee HY
Cancer Lett; 2010 Feb; 288(1):50-6. PubMed ID: 19647363
[TBL] [Abstract][Full Text] [Related]
40. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
